Bovine colostrum supplementation as a new perspective in depression and substance use disorder treatment
A randomized placebo-controlled study
Bibliographic Data
| ID | 15522810 |
|---|---|
| Authors | Krzysztof Durkalec‐Michalski (0000-0002-5041-2981, Charles University, corresponding author), Krzysztof Durkalec-Michalski, Natalia Główka (0000-0001-8449-7162), Tomasz Podgórski (0000-0001-6858-7838), Weronika Odrobny, Marcin Krawczyński (0000-0002-8515-234X, Gdansk University of Physical Education and Sport), Ryszard Botwina, Stanisław Bodzicz, Paulina M Nowaczyk (0000-0001-7724-022X) |
| Year | 2024 |
| Volume | 15 |
| Pages | 1366942-1366942 |
| Publication date | 2024-06-18 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Frontiers in Psychiatry (JOURNAL) |
| Journal identifiers | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Publisher | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2024.1366942 |
| OpenAlex | W4399782645 |
| Language | EN |
| References cited | 52 |
Introduction This randomized, placebo-controlled, double-blind, parallel study aimed to evaluate the effect of 3-month supplementation of bovine colostrum (BOV-COL; 8 x 400 mg per day) on the outcomes of depression treatment in hospitalized patients with substance use disorder (SUD). The hypothesis is that BOV-COL supplementation as an add-on treatment results in favorable alternations in selected blood inflammatory markers or neurotransmitters, leading to better depression treatment outcomes compared with placebo (PLA). Methods Patients with a Minnesota Multiphasic Personality Inventory-2 score ≥60 points were enrolled. Twenty-nine participants ( n =18 in the BOV-COL group and n =11 in the PLA group) completed the protocol. Results The mean Beck Depression Inventory-II score was significantly reduced after supplementation in both groups. However, the mean 17-point Hamilton Depression Rating Scale score was decreased in the BOV-COL group, but not in the PLA group. In the BOV-COL group, there was a reduction in interleukin (IL)-1, IL-6, IL-10, the IL-6:IL-10 ratio, IL-17, and tumor necrosis factor alpha (TNF-α), while in the PLA group only IL-6 decreased. Favorable alternations in the total count and differentials of white blood cell subsets were more pronounced in the BOV-COL. There were no changes in neurotransmitter concentrations. Conclusions BOV-COL supplementation is a promising add-on therapy in patients with depression and SUD
Anxiety · Beck Depression Inventory · Depression (economics · Placebo · Psychiatry · Randomized controlled trial · Alcoholism and Thiamine Deficiency · Medicine · Stress Responses and Cortisol · Tryptophan and brain disorders · Gastroenterology · Internal Medicine
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder
The 16-Item quick inventory of depressive symptomatology (Qids), clinician rating (Qids-C), and self-report (Qids-SR)
A Rating Scale for Depression
Understanding MMPI-2 response structure between schizophrenia and healthy individuals
The Association Between Substance Use Disorder and Depression During the Covid-19 Lockdown in Spain and the Moderating Role of Social Support
| Highly cited | No |
|---|